CSIMarket Company Name, Ticker, Customers, else..
 
Nascent Biotech Inc   (NBIO)
Other Ticker:  
 
 
Price: $0.0541 $0.00 -0.679%
Day's High: $0.051 Week Perf: -9.22 %
Day's Low: $ 0.05 30 Day Perf: -1.58 %
Volume (M): 10 52 Wk High: $ 0.22
Volume (M$): $ 1 52 Wk Avg: $0.09
Open: $0.05 52 Wk Low: $0.03



 Market Capitalization (Millions $) 9
 Shares Outstanding (Millions) 171
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -2
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Nascent Biotech Inc
Nascent Biotech Inc. is a pharmaceutical company that is relatively new and in the early stages of development. It focuses on the research, development, and commercialization of innovative therapies and drugs in the biotechnology sector. The company aims to create cutting-edge solutions to address unmet medical needs and improve patient outcomes. Although Nascent Biotech Inc. may not have an extensive track record or a wide range of products on the market yet, it shows promising potential and is dedicated to advancing the field of biotechnology through its research and development efforts.


   Company Address: 631 US Hwy 1 Suite 407 N Palm Beach 33408 FL
   Company Phone Number: 961-5656   Stock Exchange / Ticker: NBIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.04%    
BMY   -3.7%    
JNJ   -1.93%    
MRK   -3.67%    
PFE   -1.75%    
TAK   -1.64%    
• View Complete Report
   



Nascent Biotech Inc

Nascent Biotech Inc Achieves Break-Even Point in Q1 2024 Financial Report

Nascent Biotech Inc, a company specializing in major pharmaceutical preparations, recently released its financial report for the January to March 31, 2024 period. The report indicated that the company had reached a break-even point of $0.00 per share during this time frame, which was an improvement compared to the previous year and the preceding quarter. However, the revenue remained stagnant at $0.00 million, showing no significant growth from the comparable quarter a year before.
Despite the lack of revenue growth, Nascent Biotech Inc managed to reduce its net shortfall from $-0.518 million in the same quarter a year ago to $-0.513 million in the current report. Additionally, the company reported a net deficit of $-2.09 million for the fiscal year 2024, along with revenue of $0.00 million.
Nascent Biotech Inc

Nascent Biotech Inc's Financial Report Reveals Stagnant Revenue and Recurring Losses: A Closer Look at the Company's Performance



Nascent Biotech Inc, a leading biotech company, has recently released its financial report for the most recent fiscal period. Unfortunately, the financial figures presented paint a gloomy picture for investors. With stagnant revenue, recurring losses, and declining stock prices, it is crucial to analyze the company's performance and weigh the risks before considering an investment in Nascent Biotech Inc.
1. Stagnant Revenue:
Despite the passage of an entire fiscal year, Nascent Biotech Inc failed to demonstrate any progress in revenue growth. The company reported zero million dollars in revenue for the most recent fiscal period, identical to the figures reported a year earlier. This lack of revenue growth raises concerns over Nascent Biotech Inc's ability to commercialize and monetize its portfolio of products effectively.
Nascent Biotech Inc

Nascent Biotech Inc Struggles in Q2 2024 as Losses Mount and Revenue Stagnates

Nascent Biotech Inc, a biotechnology company, recently reported its financial results for the period ending September 30, 2023. The company experienced an increase in loss per share, with a loss of $-0.01 per share compared to $0.00 per share the previous year. Additionally, the company's revenue remained unchanged at $0.00 million.
These financial figures indicate that Nascent Biotech Inc faced challenges during this period, as the loss per share increased compared to the prior year and the revenue remained stagnant. It is essential to note that a loss per share can have a negative impact on investor sentiment and may indicate that the company's financial performance is struggling.
Nascent Biotech Inc

Nascent Biotech Inc Achieves Remarkable Data Milestones in Q1 2024, Demonstrating Unprecedented Sophistication



In the ever-evolving world of the stock market, it is crucial for investors to stay informed about the latest updates and performance of various companies. One such company making waves recently is Nascent Biotech Inc. (NBIO), whose financial first quarter of 2024 witnessed a notable turnaround. This article aims to highlight the compelling facts from NBIO's recent report and shed light on its overall performance.
Revenue and Earnings:
For the financial first quarter of 2024, NBIO reported earnings per share (EPS) of $0.00 compared to a negative EPS of $-0.01 a year ago. Furthermore, the revenue surged to $0.00 million, showcasing significant growth from the previous year's $0.00 million. This sequential growth indicates a positive trend for Nascent Biotech Inc.
Nascent Biotech Inc

Fourth Quarter 2023: Nascent Biotech Inc Plunges into a Revenue Black Hole


Introduction:
Nascent Biotech Inc, a prominent player in the biotechnology industry, recently released its financial results for the fiscal fourth quarter of 2023. The numbers came as a disappointment to investors, as the company reported a decline in revenue and net loss compared to the previous year. Consequently, Nascent Biotech Inc's stock experienced a significant drop of 12.5%. This article aims to examine the financial context of Nascent Biotech Inc's latest results and analyze the implications for the company.
Decline in Earnings and Revenue:
During the fiscal fourth quarter of 2023, Nascent Biotech Inc generated $0.00 per share, mirroring the performance from the previous year. However, this figure marked a decline from the prior reporting season, where the company reported a loss of $-0.01 per share. The stagnant performance in earnings does not bode well for Nascent Biotech Inc, indicating a lack of growth or improvement in its financial performance.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com